Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer

Title:Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer

Volume: 21 Issue: 10

Author(s): Jian Shi, Jingying Cao and Binhua P. Zhou

Affiliation:

Keywords: Twist, BRD4, epithelial-mesenchymal transition, basal-like breast cancer.

Abstract: As an important basic helix-loop-helix (bHLH) transcription factor, Twist associates with several physiological processes such as mesodermal development, and pathological processes such as Saethre-Chotzen syndrome. During cancer progression, Twist induces epithelial-mesenchymal transition (EMT), potentiating cancer cell invasion and metastasis. Although many studies have revealed its multiple biological roles, it remained unclear how Twist transcriptionally acti vates targeted genes. Recently we discovered tip60-mediated Twist di-acetylation in the ‘‘histone H4-mimic’’ GK-X-GK motif. The di-acetylated Twist recruits BRD4 and related transcriptional components to super-enhancer of its targeted genes during progression of basal-like breast cancer (BLBC). Here, we review this new advance of regulation and functional mechanism of Twist.

Cite this article as:

Shi Jian, Cao Jingying and Zhou P. Binhua, Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612821666141211153853